Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with MPNs.

HAEMATOLOGICA(2018)

引用 17|浏览52
暂无评分
摘要
The introduction of JAK inhibitors into clinical practice has improved outcomes for patients with myeloproliferative neoplasms (MPNs). Ruxolitinib, the only approved JAK inhibitor for MPN patients, has demonstrated an ability to decrease splenomegaly and relieve constitutional symptoms.[1][1]–[3][
更多
查看译文
关键词
Chronic Myeloproliferative Disorders,Molecular Pharmacology,Myelofibrosis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要